Meinertz T, Drexler H, Just H
Medizinische Universitätsklinik, Innere Medizin III, Kardiologie, Universität Freiburg, FRG.
Basic Res Cardiol. 1989;84 Suppl 1:177-86. doi: 10.1007/BF02650357.
Dopexamine is a newly developed sympathetic catecholamine which combines dopaminergic (DA-1) and beta 2-adrenergic agonist activity with only minor beta 1-adrenergic action. Thereby, this compound exerts systemic and preferential renal vasodilation, causing afterload reduction, increases in cardiac output, and improved renal perfusion in animals and normal volunteers. Short-term administration of dopexamine in congestive heart failure established beneficial effects in central hemodynamics, that is, reduction of systemic and pulmonary vascular resistance, combined with a decrease in LV-filling pressures and increased renal blood flow. The effect on central hemodynamics are comparable to sodium nitroprusside. With higher doses, however, heart rate may increase substantially with dopexamine along with increased myocardial oxygen consumption. Experiences with prolonged administration of this drug are scarce and have, so far, yielded conflicting results. Thus, dopexamine appears to be a promising agent in the short-term management of congestive heart failure. However, its ultimate value for prolonged administration remains to be established.
多培沙明是一种新开发的交感神经儿茶酚胺，它兼具多巴胺能（DA-1）和β2肾上腺素能激动剂活性，而β1肾上腺素能作用轻微。因此，该化合物可引起全身及肾脏优先血管舒张，降低后负荷，增加心输出量，并改善动物和正常志愿者的肾脏灌注。在充血性心力衰竭患者中短期应用多培沙明可对中心血流动力学产生有益影响，即降低全身和肺血管阻力，同时降低左心室充盈压并增加肾血流量。其对中心血流动力学的影响与硝普钠相当。然而，使用较高剂量时，多培沙明可能会使心率大幅增加，同时心肌氧耗也会增加。目前关于长期使用该药的经验较少，且迄今为止结果相互矛盾。因此，多培沙明似乎是短期治疗充血性心力衰竭的一种有前景的药物。然而，其长期使用的最终价值仍有待确定。
